芦可替尼乳膏治疗外用治疗失败的中度特应性皮炎:一项随机试验
TRuE-AD4研究显示,在既往12个月内对TCS和TCI应答不足/不耐受/禁忌的中度AD成人患者中,每日两次1.5%芦可替尼乳膏治疗8周后,IGA-TS和EASI-75应答率显著高于赋形剂,瘙痒快速改善,安全性良好。
要点
- 8周时芦可替尼组IGA-TS达61.3%,显著高于赋形剂组13.6%(p<0.0001)。
- 8周时EASI-75应答率70.0% vs 18.5%(p<0.0001)。
- 首次涂抹后15分钟即观察到当前瘙痒改善,最常见不良事件为涂抹部位痤疮(3.8%)。
核心结论
- 在TCS和TCI治疗失败的中度AD成人患者中,1.5%芦可替尼乳膏显著改善临床体征、快速改善瘙痒且耐受性良好。
研究设计与样本
- TRuE-AD4(NCT06238817)是一项随机、赋形剂对照试验,纳入241例≥18岁中度AD患者,按2:1随机接受每日两次1.5%芦可替尼乳膏或赋形剂治疗8周。
主要发现
- 第8周芦可替尼组IGA-TS为61.3%,赋形剂组为13.6%(p<0.0001)。
- 第8周芦可替尼组EASI-75为70.0%,赋形剂组为18.5%(p<0.0001)。
- 第2天瘙痒NRS较基线改善≥4分的患者比例芦可替尼组为29.8%,赋形剂组为13.7%(p=0.0072)。
- 首次涂抹后15分钟观察到当前瘙痒(无回忆)改善。
- 未发生与治疗相关的严重不良事件,芦可替尼乳膏最常见不良事件为涂抹部位痤疮(3.8%)。
关键数值与推荐
- 入选标准包括IGA为3、EASI>7、瘙痒NRS≥4、受累BSA 10%-20%、DLQI>10,且既往12个月内对TCS和TCI应答不足/不耐受/禁忌。
临床怎么用
- 对于外用TCS和TCI控制不佳、可能需系统治疗的中度AD成人患者,1.5%芦可替尼乳膏可作为升级至系统治疗前的有效外用选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently control AD signs/symptoms, and escalation to systemic therapy may be required. OBJECTIVES: Report 8-week results of ruxolitinib cream in TRuE-AD4 (NCT06238817) in patients with moderate AD who had an inadequate response/intolerance/contraindication to TCS and TCI in the past 12 months (post-TCS and -TCI). METHODS: Patients aged ≥18 years with AD, an Investigator's Global Assessment (IGA) of 3, Eczema Area and Severity Index (EASI) >7, itch numerical rating scale (NRS) ≥4, 10%-20% affected body surface area and Dermatology Life Quality Index score > 10 post-TCS and -TCI were randomized (2:1) to twice-daily 1.5% ruxolitinib cream or vehicle for 8 weeks. Coprimary endpoints at Week 8 were ≥75% improvement in EASI from baseline (EASI-75) and IGA score of 0/1 with a ≥ 2-point improvement from baseline (IGA treatment success [TS]). RESULTS: Of 241 randomized patients (mean age, 37.0 y; 54.4% female), mean EASI and itch NRS scores were 12.6 and 7.4, respectively, at baseline. At Week 8, significantly more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA-TS (61.3% vs. 13.6%; p < 0.0001) and EASI-75 (70.0% vs. 18.5%; p < 0.0001). Significantly more patients achieved a ≥ 4-point improvement in itch NRS (itch NRS4) at Day 2 (29.8% vs. 13.7%; p = 0.0072); improvement in current itch (no recall) was observed in 15 min after the first application. No treatment-related adverse events were serious, and the most common adverse event occurring with ruxolitinib cream was application site acne (3.8%). CONCLUSIONS: In adults with moderate AD post-TCS and -TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch and was well tolerated. Thus, ruxolitinib cream may represent an effective topical option before escalation to systemic therapy in patients with moderate AD. Atopic dermatitis (AD), also known as eczema, generally consists of red (inflamed), dry and itchy skin that affects about 2%–10% of adults worldwide. Patients with AD of moderate severity are usually treated with topical corticosteroid (TCS) and topical calcineurin inhibitor (TCI) creams/ointments. If these medicines are not effective, systemic treatments taken by mouth or injected are usually required. We investigated whether ruxolitinib cream is effective and safe in patients with moderate AD after failure of TCS and TCI. A total of 241 adults were recruited in Europe and North America and were asked to apply either ruxolitinib cream or nonmedicated comparator cream 2 times per day for 8 weeks. We found that patients who applied ruxolitinib cream experienced greater reductions in skin inflammation and itch than those who applied nonmedicated comparator cream over the first 8 weeks of treatment. Inflammation was reduced as early as 2 weeks (the first measurement), and itch was reduced 15 min after starting treatment. The most common side effect related to ruxolitinib cream was acne on the areas of skin where ruxolitinib cream was applied (3.8% of patients). No side effects considered related to ruxolitinib cream were serious. These study findings show that ruxolitinib cream is both effective and well‐tolerated in patients with moderate AD after failure of TCS and TCI. Therefore, ruxolitinib cream may be an alternative treatment option for patients before starting systemic treatments.
引用
- Carrascosa JM, Prajapati VH, Hong HC, et al. Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial. J Eur Acad Dermatol Venereol. 2026. PMID: 42473690. doi:10.1111/jdv.70595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。